West Pharmaceutical Services, Inc. WST
370.44
(3.16)
(0.85%)
as of 25 Sep
- Market cap
- $26.3B
- P/E
- 47.1×
Follow WST
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
West Pharmaceutical Services, Inc. (WST) Return on assets
West Pharmaceutical Services, Inc.'s return on assets over the twelve months to 30 June 2026 was 14.1%, up 1.6 percentage points from fiscal 2025 (12.5%). Over the past ten years it has ranged from 5.68% (fiscal 2015) to 21.7% (fiscal 2021); the current reading is higher than 55% of that period. That is above the Medical Instruments & Supplies industry median of 0.00% and above the Healthcare sector median of −30.9%.
Return on assets, annual
Annual
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 12.5% | (0.71) |
| FY2024 | 13.2% | (2.75) |
| FY2023 | 15.9% | (0.97) |
| FY2022 | 16.9% | (4.76) |
| FY2021 | 21.7% | 8.19 |
| FY2020 | 13.5% | 2.29 |
| FY2019 | 11.2% | 0.42 |
| FY2018 | 10.8% | 2.35 |
| FY2017 | 8.42% | 0.00 |
| FY2016 | 8.42% | 2.74 |
Against its own ten years
Low 5.68%
High 21.7%
Ten-year median
12.5%
Current reading's percentile
55
Return on assets against peers
| Company | Return on assets |
|---|---|
| RMD ResMed Inc. compare | 17.8% |
| WST West Pharmaceutical Services, Inc. | 14.1% |
| SOLV Solventum Corporation compare | 9.78% |
| COO The Cooper Companies, Inc. compare | 4.55% |
| MDLN Medline Inc. compare | 3.58% |
| ALC Alcon compare | 2.06% |
| BDX Becton, Dickinson and Company compare | 1.78% |
| RGEN Repligen Corporation compare | 1.42% |
| BAX Baxter International Inc. compare | −5.21% |
| Medical Instruments & Supplies industry median | 0.00% |
| Healthcare sector median | −30.9% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on WST
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement